NO20083029L - Alkylsulfonamid-kinoliner - Google Patents

Alkylsulfonamid-kinoliner

Info

Publication number: NO20083029L
Authority: NO; Norway
Prior art keywords: diseases; alkylsulfonamide; quinolines; inflammatory; psychoses
Prior art date: 2005-12-12

Application number

NO20083029A

Other languages

English (en)

Norwegian (no)

Inventor

Thomas Simpson

James Kang

Jeffrey Albert

Cristobal Alhambra

Gerard Koether

James Woods

Yan Li

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-12

Filing date

2008-07-04

Publication date

2008-07-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38163189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083029(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-07-04 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2008-07-09 Publication of NO20083029L publication Critical patent/NO20083029L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Hematology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20083029A 2005-12-12 2008-07-04 Alkylsulfonamid-kinoliner NO20083029L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US74943105P	2005-12-12	2005-12-12
US82101606P	2006-08-01	2006-08-01
PCT/SE2006/001408 WO2007069977A1 (en)	2005-12-12	2006-12-11	Alkylsulphonamide quinolines

Publications (1)

Publication Number	Publication Date
NO20083029L true NO20083029L (no)	2008-07-09

Family

ID=38163189

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20083029A NO20083029L (no)	2005-12-12	2008-07-04	Alkylsulfonamid-kinoliner

Country Status (20)

Country	Link
US (3)	US20080293765A1 (es)
EP (1)	EP1968944B1 (es)
JP (1)	JP5165581B2 (es)
KR (1)	KR20080075867A (es)
AR (1)	AR056890A1 (es)
AU (1)	AU2006325572B2 (es)
BR (1)	BRPI0619746A2 (es)
CA (1)	CA2633129A1 (es)
DK (1)	DK1968944T3 (es)
EC (1)	ECSP088546A (es)
ES (1)	ES2571834T3 (es)
HU (1)	HUE029805T2 (es)
IL (1)	IL191628A0 (es)
NO (1)	NO20083029L (es)
PL (1)	PL1968944T3 (es)
PT (1)	PT1968944T (es)
RU (1)	RU2421447C2 (es)
TW (2)	TW200804288A (es)
UY (1)	UY30001A1 (es)
WO (1)	WO2007069977A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200804288A (en) *	2005-12-12	2008-01-16	Astrazeneca Ab	Alkylsulphonamide quinolines
JP5399518B2 (ja) *	2009-01-30	2014-01-29	エフ．ホフマン−ラロシュアーゲー	Ｎｋ３レセプターアンタゴニストとしてのピペリジン誘導体
CA2833232C (en)	2011-04-15	2018-05-22	University Of Massachusetts	Surgical cavity drainage and closure system
EP2806820B1 (en)	2012-01-24	2022-10-12	Smith&Nephew, Inc.	Porous structure and methods of making same
BR112015026519A2 (pt)	2013-04-19	2017-07-25	Astrazeneca Ab	composto antagonista do receptor nk3 (nk3ra) para uso em um método destinado ao tratamento de síndrome do ovário policístico (sop)
GB201315846D0 (en) *	2013-09-05	2013-10-23	Imp Innovations Ltd	Method for treating or preventing hot flushes
GB201503207D0 (en)	2015-02-26	2015-04-15	Univ Edinburgh	Female health compounds

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0133244B1 (en) *	1983-07-22	1990-12-05	E.I. Du Pont De Nemours And Company	Phenylquinolinecarboxylic acids and derivatives as antitumor agents
US5177096A (en) *	1989-10-25	1993-01-05	Smithkline Beecham Corporation	Substituted 5-((tetrazolyl)alkenyl)imidazoles and pharmaceutical methods of use thereof
US5248689A (en) *	1989-11-06	1993-09-28	Smithkline Beecham Corporation	Substituted N-(imidazolyl)alkyl alanine derivatives
NZ238688A (en)	1990-06-28	1992-05-26	Smithkline Beecham Corp	Substituted histidines: pharmaceutical compositions, preparation and uses thereof
MX9300141A (es) *	1992-01-13	1994-07-29	Smithkline Beecham Corp	Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
FR2719311B1 (fr) *	1994-03-18	1998-06-26	Sanofi Sa	Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
DE69531458T2 (de)	1994-05-27	2004-08-05	Glaxosmithkline S.P.A.	Chinolinderivate als tachykinin nk3 rezeptor antagonisten
IT1270615B (it)	1994-07-14	1997-05-07	Smithkline Beecham Farma	Uso di derivati di chinolina
SK56798A3 (en) *	1995-10-30	1998-12-02	Smithkline Beecham Corp	Protease inhibitors, pharmaceutical composition containing them and their use
AR004735A1 (es)	1995-11-24	1999-03-10	Smithkline Beecham Spa	Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
NZ323387A (en)	1995-11-24	2000-02-28	Smithkline Beecham Spa	Quinoline derivatives having neurokinin antagonist activity, preparation and use thereof
GB9524104D0 (en)	1995-11-24	1996-01-24	Smithkline Beecham Spa	Novel compounds
GB9524137D0 (en)	1995-11-24	1996-01-24	Smithkline Beecham Spa	Novel compounds
US6096739A (en) *	1996-03-25	2000-08-01	Smithkline Beecham Corporation	Treatment for CNS injuries
CO5040088A1 (es)	1998-04-03	2001-05-29	Advanced Medicine Inc	Nuevos compuestos y usos anestesicos locales
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
AU768708B2 (en) *	1998-11-20	2004-01-08	Smithkline Beecham Laboratoires Pharmaceutiques	Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
AU4802500A (en)	1999-04-26	2000-11-10	Neurogen Corporation	2-aminoquinolinecarboxamides: neurokinin receptor ligands
EP1181288B1 (en) *	1999-05-27	2003-07-30	PHARMACIA & UPJOHN COMPANY	Bicyclic oxazolidinones as antibacterial agent
US6858630B2 (en) *	1999-12-06	2005-02-22	Smithkline Beecham Corporation	Naphthimidazole derivatives and their use as thrombopoietin mimetics
US6248136B1 (en) *	2000-02-03	2001-06-19	Micell Technologies, Inc.	Methods for carbon dioxide dry cleaning with integrated distribution
AU2001276556A1 (en)	2000-08-11	2002-02-25	Smithkline Beecham P.L.C.	Novel pharmaceutical use of quinnoline derivatives
EP1192952A3 (en)	2000-09-28	2003-03-26	Pfizer Products Inc.	Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
EP1415987B1 (en)	2000-10-20	2007-02-28	Eisai R&D Management Co., Ltd.	Nitrogenous aromatic ring compounds as anti cancer agents
GB0027701D0 (en) *	2000-11-13	2000-12-27	Smithkline Beecham Spa	Novel compounds
MY134211A (en)	2001-05-18	2007-11-30	Smithkline Beecham Corp	Novel use
US20040006135A1 (en) *	2002-06-19	2004-01-08	Pfizer Inc.	Combination treatment for depression and anxiety
GB0228287D0 (en)	2002-12-04	2003-01-08	Smithkline Beecham Corp	Chemical compounds
GB0228288D0 (en)	2002-12-04	2003-01-08	Smithkline Beecham Corp	Chemical compounds
EP2258365B1 (en)	2003-03-28	2013-05-29	Novartis Vaccines and Diagnostics, Inc.	Use of organic compounds for immunopotentiation
CN1832920A (zh)	2003-08-08	2006-09-13	特兰斯泰克制药公司	芳基和杂芳基化合物,组合物及其使用方法
US7459472B2 (en)	2003-08-08	2008-12-02	Transtech Pharma, Inc.	Aryl and heteroaryl compounds, compositions, and methods of use
EP1661889A4 (en)	2003-09-05	2009-08-05	Ono Pharmaceutical Co	ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
EP1729751A1 (en)	2004-03-25	2006-12-13	Smithkline Beecham Corporation	Use of an nk3 antagonist for the treatment of bipolar disorders
CA2565843A1 (en)	2004-05-06	2005-11-17	Pfizer Inc.	Novel compounds of proline and morpholine derivatives
GB0425077D0 (en)	2004-11-12	2004-12-15	Smithkline Beecham Corp	Novel compounds
GB0509405D0 (en)	2005-05-10	2005-06-15	Merck Sharp & Dohme	Therapeutic compounds
CA2613001A1 (en) *	2005-06-23	2006-12-28	Astrazeneca Ab	Quinoline 3 -sulfonate esters as nk3 receptor modulators
CN101287723A (zh) *	2005-08-11	2008-10-15	阿斯利康(瑞典)有限公司	作为nk3受体调节剂的酰胺烷基吡啶基喹啉
EP1922406A4 (en)	2005-08-12	2008-12-31	Univ California	INHIBITION OF THE AMINO ACID PHOSPHATASE ACTIVITY OF A SOLUBLE HYDROLASE EPOXY AND APPLICATIONS
AR058051A1 (es) *	2005-09-21	2008-01-23	Astrazeneca Ab	Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
TW200804288A (en) *	2005-12-12	2008-01-16	Astrazeneca Ab	Alkylsulphonamide quinolines
CN101410392A (zh) *	2006-01-27	2009-04-15	阿斯利康(瑞典)有限公司	酰胺取代的喹啉类化合物
PE20080906A1 (es)	2006-08-17	2008-07-05	Kemia Inc	Derivados heteroarilo como inhibidores de citocina

2006
- 2006-12-05 TW TW095145166A patent/TW200804288A/zh unknown
- 2006-12-05 TW TW099103065A patent/TW201018662A/zh unknown
- 2006-12-11 WO PCT/SE2006/001408 patent/WO2007069977A1/en not_active Ceased
- 2006-12-11 JP JP2008545536A patent/JP5165581B2/ja not_active Expired - Fee Related
- 2006-12-11 PT PT68358332T patent/PT1968944T/pt unknown
- 2006-12-11 HU HUE06835833A patent/HUE029805T2/en unknown
- 2006-12-11 US US12/096,997 patent/US20080293765A1/en not_active Abandoned
- 2006-12-11 BR BRPI0619746-9A patent/BRPI0619746A2/pt not_active IP Right Cessation
- 2006-12-11 AR ARP060105444A patent/AR056890A1/es not_active Application Discontinuation
- 2006-12-11 EP EP06835833.2A patent/EP1968944B1/en active Active
- 2006-12-11 UY UY30001A patent/UY30001A1/es unknown
- 2006-12-11 CA CA002633129A patent/CA2633129A1/en not_active Abandoned
- 2006-12-11 ES ES06835833T patent/ES2571834T3/es active Active
- 2006-12-11 DK DK06835833.2T patent/DK1968944T3/en active
- 2006-12-11 PL PL06835833.2T patent/PL1968944T3/pl unknown
- 2006-12-11 US US11/609,166 patent/US7608628B2/en not_active Expired - Fee Related
- 2006-12-11 AU AU2006325572A patent/AU2006325572B2/en not_active Ceased
- 2006-12-11 KR KR1020087014020A patent/KR20080075867A/ko not_active Withdrawn
- 2006-12-11 RU RU2008121761/04A patent/RU2421447C2/ru not_active IP Right Cessation
2008
- 2008-05-22 IL IL191628A patent/IL191628A0/en unknown
- 2008-06-13 EC EC2008008546A patent/ECSP088546A/es unknown
- 2008-07-04 NO NO20083029A patent/NO20083029L/no not_active Application Discontinuation
2009
- 2009-10-09 US US12/576,319 patent/US8071621B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ECSP088546A (es)	2008-07-30
IL191628A0 (en)	2008-12-29
BRPI0619746A2 (pt)	2011-10-11
CA2633129A1 (en)	2007-06-21
RU2008121761A (ru)	2010-01-20
EP1968944A1 (en)	2008-09-17
US20100029717A1 (en)	2010-02-04
WO2007069977A1 (en)	2007-06-21
AU2006325572B2 (en)	2011-02-24
HUE029805T2 (en)	2017-03-28
ES2571834T3 (es)	2016-05-27
EP1968944A4 (en)	2011-01-12
AU2006325572A1 (en)	2007-06-21
US20080021062A1 (en)	2008-01-24
US20080293765A1 (en)	2008-11-27
HK1121759A1 (zh)	2009-04-30
US7608628B2 (en)	2009-10-27
US8071621B2 (en)	2011-12-06
JP5165581B2 (ja)	2013-03-21
PL1968944T3 (pl)	2016-11-30
TW201018662A (en)	2010-05-16
EP1968944B1 (en)	2016-04-20
KR20080075867A (ko)	2008-08-19
UY30001A1 (es)	2007-07-31
DK1968944T3 (en)	2016-08-01
RU2421447C2 (ru)	2011-06-20
PT1968944T (pt)	2016-07-29
AR056890A1 (es)	2007-10-31
JP2009519331A (ja)	2009-05-14
TW200804288A (en)	2008-01-16

Publication	Publication Date	Title
NO20083029L (no)	2008-07-09	Alkylsulfonamid-kinoliner
Więckowska et al.	2016	Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation
NO20064888L (no)	2006-10-26	Heterocykliske CGRP antagonister for behandling av migrene
DE602007004750D1 (de)	2010-03-25	Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
NO20082026L (no)	2008-06-25	Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
ATE508126T1 (de)	2011-05-15	Als kinaseinhibitoren geeignete aminopyrimidine
TW200628470A (en)	2006-08-16	Constrained compounds as CGRP-receptor antagonists
NO20072918L (no)	2007-07-05	Heteroaromatiske quinolinforbindelser, og anvendelse av disse som inhibitorer av PDE10
MY160471A (en)	2017-03-15	New ccr2 receptor antagonists and uses thereof
DE602007007985D1 (de)	2010-09-02	Als inhibitoren von proteinkinasen geeignete aminopyrimidine
NO20060534L (no)	2006-04-03	Heterosyklisk substituerte pentanolderivater, fremgangsmate for fremstilling av disse, og anvendelse av disse som anti-inflammatoriske midler
NO20091588L (no)	2009-05-28	Kjemisk prosess
NO20072963L (no)	2007-08-03	5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
DE602005010970D1 (de)	2008-12-24	Indol-derivate und ihre verwendung als kinase-hemmer, insbesondere ikk2-hemmer
ATE526328T1 (de)	2011-10-15	Als inhibitoren von proteinkinasen geeignete aminopyrimidine
MX2007014619A (es)	2009-02-13	Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
NO20070321L (no)	2007-03-12	Pyridazin-3(2H)-on-derivater og deres anvendelse som PDE4-inhibitorer
NO20065948L (no)	2007-01-23	Quinazolin-4-yl-piperidin- and cinnolin-4-yl-piperidin-derivatives som PDE10-inhibitorer for behandling av CNS forstyrrelser
ATE544767T1 (de)	2012-02-15	Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten
ATE497961T1 (de)	2011-02-15	Als proteinkinaseinhibitoren geeignete verbindungen
NO20083918L (no)	2008-11-12	Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
NO20070319L (no)	2007-03-06	Nye pyridazin-3(2H)-on-derivater og deres anvendelse som PDE4-inhibitorer
WO2008063202A3 (en)	2009-01-22	Heterobicyclic thiophene compounds for the treatment of cancer
NO20076634L (no)	2008-02-29	Erythropoietin reseptorpeptidformuleringer og anvendelser
MX2010007392A (es)	2010-10-05	Antagonistas de trpa1.

Legal Events

Date	Code	Title	Description
2012-07-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application